Abbonarsi

Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease - 11/02/19

Doi : 10.1016/j.jaad.2018.08.052 
Yoshiko Mizukawa, MD, PhD a, , Kazuhisa Hirahara, MD, PhD a, b, Yoko Kano, MD, PhD a, Tetsuo Shiohara, MD, PhD a
a Department of Dermatology at Kyorin University School of Medicine, Shinkawa, Mitaka, Tokyo, Japan 
b Department of Dermatology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan 

Reprint requests: Yoshiko Mizukawa, MD, Department of Dermatology, Kyorin University School of Medicine, Shinkawa, 6-20-2, Mitaka, Tokyo 181-8611, Japan.Department of DermatologyKyorin University School of MedicineShinkawa, 6-20-2, MitakaTokyo181-8611Japan

Abstract

Background

The prognosis of drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) is highly unpredictable. Severe complications, either related or unrelated to cytomegalovirus (CMV) reactivation, are a highly probable cause of death.

Objectives

The aim was to establish a scoring system for DiHS/DRESS that can be used to monitor severity, predict prognosis, and stratify the risk of developing CMV disease and complications.

Methods

A retrospective analysis of 55 patients with DiHS/DRESS was performed. A composite score was created using clinical data. DiHS/DRESS patients were also stratified into 3 groups based on the scores to predict the risk of CMV reactivation and complications.

Results

This scoring system made it possible to predict CMV disease and complications. Scores ≥4 were associated with the later development of CMV disease and complications, while no patients with scores <4 developed complications.

Limitations

This was a single-institution study with a relatively small patient cohort that lacked a validation cohort.

Conclusions

Our scoring system may be useful for predicting CMV-related complications, and early intervention with anti-CMV agents should be considered in patients with scores ≥4 or with evidence of CMV reactivation.

Il testo completo di questo articolo è disponibile in PDF.

Key words : CMV reactivation, disease severity, drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS), prognosis, scoring system


Mappa


 Supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology and the Health and Labour Sciences Research Grants (Research on Intractable Diseases) from the Ministry of Health, Labour and Welfare, Japan (Dr Shiohara).
 Conflicts of interest: None disclosed.


© 2018  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 80 - N° 3

P. 670 - marzo 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma
  • Manuel António Campos, Sofia Macedo, Margarida Fernandes, Ana Pestana, Joana Pardal, Rui Batista, João Vinagre, Agostinho Sanches, Armando Baptista, José Manuel Lopes, Paula Soares
| Articolo seguente Articolo seguente
  • Bundled payment for actinic keratosis management: Pilot evaluation of developed models
  • Joslyn S. Kirby, Colleen F. Silva, Sara B. Ferguson, David Shupp, James G. Marks, Jeffrey J. Miller

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.